In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas - PubMed (original) (raw)
. 2014 May 15;20(10):2773-82.
doi: 10.1158/1078-0432.CCR-13-2702. Epub 2014 Mar 19.
Affiliations
- PMID: 24647569
- DOI: 10.1158/1078-0432.CCR-13-2702
In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas
Kurt A Schalper et al. Clin Cancer Res. 2014.
Abstract
Purpose: Blockade of the PD-1/PD-L1 axis emerged as a promising new therapeutic option for cancer that has resulted in lasting responses in metastatic renal, lung carcinomas, and melanomas. Tumor PD-L1 protein expression may predict response to drugs targeting this pathway. Measurement of PD-L1 protein is limited by the lack of standardized immunohistochemical methods and variable performance of antibodies. Our goal was to correlate PD-L1 mRNA expression with clinical variables in primary breast carcinomas.
Experimental design: The fluorescent RNAscope paired-primer assay was used to quantify in situ PD-L1 mRNA levels in 636 stage I-III breast carcinomas on two sets of tissue microarrays [YTMA128 (n = 238) and YTMA201 (n = 398)]. Tumor-infiltrating lymphocytes (TIL) were assessed by hematoxylin/eosin stain and quantitative fluorescence.
Results: On YTMA128 and YTMA201, 55.7% and 59.5% of cases showed PD-L1 mRNA expression, respectively. Higher PD-L1 mRNA expression was significantly associated with increased TILs (P = 0.04) but not with other clinical variables. Elevated TILs (scores 2 and 3+) occurred in 16.5% on YTMA128 and 14.8% on YTMA201 and was associated with estrogen receptor-negative status (P = 0.01 on YTMA128 and 0.0001 on YTMA201). PD-L1 mRNA expression was associated with longer recurrence-free survival (log-rank P = 0.01), which remained significant in multivariate analysis including age, tumor size, histologic grade, nodal metastasis, hormone receptor, HER2 status, and the extent of TILs (HR, 0.268; CI, 0.099-0.721; P = 0.009).
Conclusions: PD-L1 mRNA expression is identified in nearly 60% of breast tumors and it is associated with increased TILs and improved recurrence-free survival. These observations support the evaluation of PD-1/PD-L1-targeted therapies in breast cancer.
©2014 American Association for Cancer Research.
Similar articles
- Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
Vassilakopoulou M, Avgeris M, Velcheti V, Kotoula V, Rampias T, Chatzopoulos K, Perisanidis C, Kontos CK, Giotakis AI, Scorilas A, Rimm D, Sasaki C, Fountzilas G, Psyrri A. Vassilakopoulou M, et al. Clin Cancer Res. 2016 Feb 1;22(3):704-13. doi: 10.1158/1078-0432.CCR-15-1543. Epub 2015 Sep 25. Clin Cancer Res. 2016. PMID: 26408403 - Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Budczies J, Bockmayr M, Dietel M, Denkert C, Braicu I, Jöhrens K. Darb-Esfahani S, et al. Oncotarget. 2016 Jan 12;7(2):1486-99. doi: 10.18632/oncotarget.6429. Oncotarget. 2016. PMID: 26625204 Free PMC article. - Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH, Kong SY, Ro JY, Kwon Y, Kang JH, Mo HJ, Jung SY, Lee S, Lee KS, Kang HS, Lee E, Joo J, Ro J. Park IH, et al. Clin Breast Cancer. 2016 Feb;16(1):51-8. doi: 10.1016/j.clbc.2015.07.006. Epub 2015 Aug 6. Clin Breast Cancer. 2016. PMID: 26364145 - Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.
Huang W, Ran R, Shao B, Li H. Huang W, et al. Breast Cancer Res Treat. 2019 Nov;178(1):17-33. doi: 10.1007/s10549-019-05371-0. Epub 2019 Jul 29. Breast Cancer Res Treat. 2019. PMID: 31359214 Review. - The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.
Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, Kazkaz GA. Ibrahim EM, et al. Breast Cancer Res Treat. 2014 Dec;148(3):467-76. doi: 10.1007/s10549-014-3185-2. Epub 2014 Nov 1. Breast Cancer Res Treat. 2014. PMID: 25361613 Review.
Cited by
- Sex differences in survival outcomes of early-onset colorectal cancer.
Afify AY, Ashry MH, Hassan H. Afify AY, et al. Sci Rep. 2024 Sep 26;14(1):22041. doi: 10.1038/s41598-024-71999-8. Sci Rep. 2024. PMID: 39327445 Free PMC article. - Advancements in Understanding the Hide-and-Seek Strategy of Hibernating Breast Cancer Cells and Their Implications in Oncology from a Broader Perspective: A Comprehensive Overview.
Al-Ruwishan A, Amer B, Salem A, Abdi A, Chimpandu N, Esa A, Melemenis A, Saleem MZ, Mathew R, Gamallat Y. Al-Ruwishan A, et al. Curr Issues Mol Biol. 2024 Aug 1;46(8):8340-8367. doi: 10.3390/cimb46080492. Curr Issues Mol Biol. 2024. PMID: 39194709 Free PMC article. Review. - Association of clinicopathologic and sonographic features with stromal tumor-infiltrating lymphocytes in triple-negative breast cancer.
Hu L, Gu Y, Xu W, Wang C. Hu L, et al. BMC Cancer. 2024 Aug 12;24(1):997. doi: 10.1186/s12885-024-12778-6. BMC Cancer. 2024. PMID: 39135184 Free PMC article. - Relationship Between PD-L1, PD-1, CD8 and Clinicopathological Factors in Primary SCCs.
Vasilev P, Popovska S, Petrova Kraevska E, Karamanliev M, Dimitrov D, Yordanova I. Vasilev P, et al. Dermatol Pract Concept. 2024 Jul 1;14(3):e2024176. doi: 10.5826/dpc.1403a176. Dermatol Pract Concept. 2024. PMID: 39122531 Free PMC article. - Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
Wescott EC, Sun X, Gonzalez-Ericsson P, Hanna A, Taylor BC, Sanchez V, Bronzini J, Opalenik SR, Sanders ME, Wulfkuhle J, Gallagher RI, Gomez H, Isaacs C, Bharti V, Wilson JT, Ballinger TJ, Santa-Maria CA, Shah PD, Dees EC, Lehmann BD, Abramson VG, Hirst GL, Brown Swigart L, van ˈt Veer LJ, Esserman LJ, Petricoin EF, Pietenpol JA, Balko JM. Wescott EC, et al. Cancer Res Commun. 2024 Apr 24;4(4):1120-1134. doi: 10.1158/2767-9764.CRC-23-0468. Cancer Res Commun. 2024. PMID: 38687247 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous